Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLB1 | P16278 | 1/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.44 |
| ▸ | GBA1 | P04062 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.41 |
| ▸ | GUSB | P08236 | 2/20 | 0.41 |
| ▸ | EBP | Q15125 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6066308 | 1.00 | GLB1 (0.48) | GLB1GNAI3GNAO1GNAI1GBA1 | |
| SCHEMBL3242510 | 1.00 | GLB1 (0.48) | GLB1GNAI3GNAO1GNAI1GBA1 | |
| SCHEMBL3231907 | 1.00 | GLB1 (0.48) | GLB1GNAI3GNAO1GNAI1GBA1 | |
| SCHEMBL13377081 | 0.87 | GLB1 (0.56) | GLB1GNAI3GNAO1GNAI1GBA1 | |
| SCHEMBL21701406 | 0.82 | — | — | |
| SCHEMBL13291907 | 0.81 | GLB1 (0.50) | GLB1GNAI3GNAO1GNAI1GBA1 | |
| SCHEMBL20858275 | 0.78 | GUSB (0.59) | GLB1GNAI3GNAO1GNAI1GBA1 | |
| SCHEMBL20858345 | 0.78 | GUSB (0.59) | GLB1GNAI3GNAO1GNAI1GBA1 | |
| SCHEMBL19275301 | 0.78 | GUSB (0.59) | GLB1GNAI3GNAO1GNAI1GBA1 | |
| SCHEMBL12524618 | 0.78 | SMN1; SMN2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745462-B2 | Quinoline-2-one derivatives for the treatment of airways diseases | NOVARTIS AG (CH) | 2010-06-29 | — | — | US | disclosed |
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | NOVARTIS AG (CH) | 2007-03-22 | — | — | US | disclosed |
| EP-1613315-A1 | QUINOLINE-2-ONE-DERIVATIVES FOR THE TREATMENT OF AIRWAYS DISEASES | Novartis AG (CH) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087142-A1 | QUINOLINE-2-ONE-DERIVATIVES FOR THE TREATMENT OF AIRWAYS DISEASES | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066607-A1 | Quinoline-2-one derivatives for the treatment of airways diseases | ADRB2, ADRA2C, ADRB1 | GLB1 2086/4885GNAI3 182/4885GNAO1 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.